Enzo Biochem, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Segment reporting (Tables)

Segment reporting (Tables)

9 Months Ended

Apr. 30, 2013

Schedule of Segment Reporting Information, by Segment [Table Text Block]

The following financial information represents the operating results of the reportable segments of the Company:

Three months ended April 30, 2013
	Clinical Labs			Life Sciences			Therapeutics			Other			Consolidated
Revenues:
Clinical laboratory services	$	13,384			—			—			—		$	13,384
Product revenues		—		$	8,265			—			—			8,265
Royalty and license fee income		—			949			—			—			949
		13,384			9,214			—			—			22,598
Operating expenses:
Cost of clinical laboratory services		9,331			—			—			—			9,331
Cost of product revenues		—			4,219			—			—			4,219
Research and development		61			625		$	303			—			989
Selling, general and administrative		5,041			3,813			—		$	2,178			11,032
Provision for uncollectible accounts receivable		887			41			—			—			928
Legal		115			21			—			1,572			1,708
Total operating expenses		15,435			8,719			303			3,750			28,207

Operating income (loss)		(2,051	)		495			(303	)		(3,750	)		(5,609	)

Other income (expense)
Interest		(12	)		2			—			—			(10	)
Other		6			12			—			7			25
Foreign currency income (loss)		—			(214	)		—			—			(214	)
Income (loss) before income taxes	$	(2,057	)	$	295		$	(303	)	$	(3,743	)	$	(5,808	)

Depreciation and amortization included above	$	354		$	778		$	4		$	25		$	1,161

Share-based compensation included in above:
Cost of clinical laboratory services	$	2			—			—			—		$	2
Research and development		—			1			—			—			1
Selling, general and administrative		11		$	—			—		$	126			137
Total	$	13		$	1			—		$	126		$	140

Capital expenditures	$	148		$	18		$	—		$	—		$	166

Three months ended April 30, 2012
	Clinical Labs			Life Sciences			Therapeutics			Other			Consolidated
Revenues:
Clinical laboratory services	$	15,242			—			—			—		$	15,242
Product revenues		—		$	9,574			—			—			9,574
Royalty and license fee income		—			1,133			—			—			1,133
		15,242			10,707			—			—			25,949
Operating expenses:
Cost of clinical laboratory services		9,204			—			—			—			9,204
Cost of product revenues		—			4,689			—			—			4,689
Research and development		109			940		$	539			—			1,588
Selling, general and administrative		5,301			4,369			—		$	2,184			11,854
Provision for uncollectible accounts receivable		1,153			40			—			—			1,193
Legal		102			27			—			814			943
Total operating expenses		15,869			10,065			539			2,998			29,471

Operating income (loss)		(627	)		642			(539	)		(2,998	)		(3,522	)

Other income (expense)
Interest		(2	)		(16	)		—			—			(18	)
Other		9			—			—			6			15
Foreign currency gain (loss)		—			80			—			—			80
Income (loss) before income taxes	$	(620	)	$	706		$	(539	)	$	(2,992	)	$	(3,445	)

Depreciation and amortization included above	$	275		$	710		$	11		$	31		$	1,027

Share-based compensation included in above:
Cost of clinical laboratory services	$	3			—			—			—		$	3
Research and development		—		$	1			—			—			1
Selling, general and administrative		16			10			—		$	138			164
Total	$	19		$	11			—		$	138		$	168

Capital expenditures	$	264		$	177		$	—		$	—		$	441

Nine months ended April 30, 2013
	Clinical Labs			Life Sciences		Therapeutics			Other			Consolidated
Revenues:
Clinical laboratory services	$	41,881			—		—			—		$	41,881
Product revenues		—		$	24,574		—			—			24,574
Royalty and license fee income		—			3,982		—			—			3,982
		41,881			28,556		—			—			70,437
Operating expenses:
Cost of clinical laboratory services		28,466			—		—			—			28,466
Cost of product revenues		—			12,546		—			—			12,546
Research and development		236			1,800	$	932			—			2,968
Selling, general and administrative		14,914			12,165		—		$	6,261			33,340
Provision for uncollectible accounts receivable		3,656			201		—			—			3,857
Legal		272			58		—			4,520			4,850
Total operating expenses		47,544			26,770		932			10,781			86,027

Operating income (loss)		(5,663	)		1,786		(932	)		(10,781	)		(15,590	)

Other income (expense)
Interest		(34	)		6		—			3			(25	)
Other		31			32		—			18			81
Foreign currency income (loss)		—			119		—			—			119
Income (loss) before income taxes	$	(5,666	)	$	1,943	$	(932	)	$	(10,760	)	$	(15,415	)

Depreciation and amortization included above	$	1,017		$	2,382	$	19		$	79		$	3,497

Share-based compensation included in above:
Cost of clinical laboratory services	$	7			—		—			—		$	7
Research and development		—		$	2		—			—			2
Selling, general and administrative		37			6		—		$	389			432
Total	$	44		$	8		—		$	389		$	441

Capital expenditures	$	579		$	193	$	—		$	—		$	772

Nine months ended April 30, 2012
	Clinical Labs			Life Sciences			Therapeutics			Other			Consolidated
Revenues:
Clinical laboratory services	$	43,552			—			—			—		$	43,552
Product revenues		—		$	28,819			—			—			28,819
Royalty and license fee income		—			4,302			—			—			4,302
		43,552			33,121			—			—			76,673
Operating expenses:
Cost of clinical laboratory services		26,728			—			—			—			26,728
Cost of product revenues		—			14,511			—			—			14,511
Research and development		224			3,125		$	1,567			—			4,916
Selling, general and administrative		15,322			13,824			—		$	6,581			35,727
Provision for uncollectible accounts receivable		3,571			77			—			—			3,648
Legal		214			529			—			2,092			2,835
Total operating expenses		46,059			32,066			1,567			8,673			88,365

Operating income (loss)		(2,507	)		1,055			(1,567	)		(8,673	)		(11,692	)

Other income (expense)
Interest		(3	)		(3	)		—			—			(6	)
Other		33			42			—			19			94
Foreign currency gain (loss)		—			(243	)		—			—			(243	)
Income (loss) before income taxes	$	(2,477	)	$	851		$	(1,567	)	$	(8,654	)	$	(11,847	)

Depreciation and amortization included above	$	810		$	2,350		$	33		$	93		$	3,286

Share-based compensation included in above:
Cost of clinical laboratory services	$	8			—			—			—		$	8
Research and development		—		$	4			—			—			4
Selling, general and administrative		41			51			—		$	491			583
Total	$	49		$	55			—		$	491		$	595

Capital expenditures	$	695		$	284		$	—		$	—		$	979

- Definition

Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.

+ References + Details